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Cerebral malaria (CM) is a life-threatening complication of falciparum malaria, associated with high mortality rates,
as well as neurological impairment in surviving patients. Despite disease severity, the etiology of CM remains
elusive. Interestingly, although the Plasmodium parasite is sequestered in cerebral microvessels, it does not enter
the brain parenchyma: so how does Plasmodium induce neuronal dysfunction? Several independent research
groups have suggested a mechanism in which increased blood–brain barrier (BBB) permeability might allow toxic
molecules from the parasite or the host to enter the brain. However, the reported severity of BBB damage in CM is
variable depending on the model system, ranging from mild impairment to full BBB breakdown. Moreover, the
factors responsible for increased BBB permeability are still unknown. Here we review the prevailing theories on CM
pathophysiology and discuss new evidence from animal and human CM models implicating BBB damage. Finally,
we will review the newly-described role of matrix metalloproteinases (MMPs) and BBB integrity. MMPs comprise a
family of proteolytic enzymes involved in modulating inflammatory response, disrupting tight junctions, and
degrading sub-endothelial basal lamina. As such, MMPs represent potential innovative drug targets for CM.
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InflammationIntroduction
Human malaria is a widespread infectious disease caused
by Plasmodium protozoan parasites and is associated with
high morbidity and mortality rates, resulting in 627,000
deaths among 207 million cases estimated in 2012 [1].
Human malaria is caused by five different Plasmodium
species: P. falciparum, P. malariae, P. ovale, P. vivax and
P. knowlesi. P. falciparum and P. vivax are the most com-
mon, correlating with the most severe forms of malaria
and the highest death rate, whereas other Plasmodium
species generally cause milder forms of malaria which are
rarely fatal [1]. The majority of deaths occur among chil-
dren under the age of five years living in sub-Saharan
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article, unless otherwise stated.Southern America where mortality mainly affects adults.
Additionally, occasional cases are observed in non-immune
adult travelers from developed countries returning from
these areas. Despite the intense efforts made by the re-
search community and the Global Eradication program [2],
no effective vaccines or adjuvant therapies are available for
complicated malaria. It is projected that in the next few
years the dramatic issue of drug-resistant malaria could be-
come a serious threat [3-5].
P. falciparum is unique in that it causes mature in-
fected red blood cells (iRBCs) to sequester and adhere to
microvascular beds in numerous organs. A paradigmatic
complication of falciparum malaria is cerebral malaria
(CM), which develops after iRBCs sequester in the mi-
crovasculature of the central nervous system (CNS). Un-
like the other human malarial parasites which rarely
cause neurological dysfunction, P. falciparum-induced
CM often leads to death or severe neurological sequelae
[6]. Curiously, P. falciparum appears to remain in the vas-
cular space without ever entering the brain parenchyma,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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as Trypanosoma spp. or Toxoplasma gondii [7], thus rais-
ing question of how intravascular Plasmodium parasites
are capable of inducing such a devastating neural dysfunc-
tion in CM.
Recent evidence suggests that a compromised integrity
of the blood–brain barrier (BBB) results in a subsequent
increase in BBB permeability which enables toxic soluble
factors released either by host or parasite to cross this
barrier and exert neurological effects. This review fo-
cuses on CM pathophysiology and novel insights from
animal and human models into the role of BBB func-
tional impairment in CM. Finally, we discuss the emer-
ging role of host matrix metalloproteinases (MMPs), a
family of proteolytic enzymes related to inflammation
and BBB damage in CM, opening the possibility for dis-
covery of new effective adjuvant therapies for CM.
Pathophysiology of cerebral malaria
CM appears as a diffuse encephalopathy commonly pre-
senting with headache, agitation, frank psychosis, sei-
zures and impaired consciousness, and occasionally with
brainstem signs or focal neurological signs such as hemi-
plegia and cranial nerve palsies [8,9]. According to the
World Health Organization (WHO) clinical criteria, CM
is defined as a potentially reversible, diffuse encephalop-
athy causing a Glasgow coma score of 11/15 or less,
often associated with fitting, in the absence of other fac-
tors that could cause unconsciousness such as coexistentFigure 1 Most commonly accepted hypotheses for pathophysiologica
malaria (CM). The diagram summarizes the three distinct hypotheses on C
associated with iRBC cytoadherence and their reduced deformability, causi
ii) the permeability hypothesis is based on BBB impairment and subsequen
the brain parenchyma and causing neurological dysfunction; iii) the humor
pro-inflammatory molecules, including cytokines and chemokines, and oth
inflammation, fever and coma during CM.hypoglycemia or other CNS infections [10]. It is difficult
to confirm diagnoses of CM in endemic areas because of
overlapping infections such as bacterial meningitis in
patients showing incidental malarial parasitaemia [11].
Children from areas endemic for malaria or non-immune
adults traveling from developed countries are at higher
risk for developing CM. On the contrary, CM is rarely en-
countered in > 10-year-old patients who have been ex-
posed to P. falciparum since birth. Mortality ranges from
15–30%, and 11% of children display neurological deficits
upon discharge [12].
The pathophysiological mechanisms underlying CM
are not fully understood so far. As seen in Figure 1 and
discussed in the next paragraphs, there are currently
three distinct theories on the etiology of CM typical fea-
tures: i) the mechanical hypothesis; ii) the permeability
hypothesis; and iii) the humoral hypothesis [4,9,13-16].
It is possible that these theories are all pieces of that
puzzle that need to be combined as they likely constitute
more complementary than alternative models [6,17].
Mechanical hypothesis
The mechanical hypothesis proposes CM is caused by a
mechanical obstruction of the cerebral microvasculature,
with coma resulting from impaired brain perfusion [9,14,18].
Such a hypothesis was made after one of the first
pathological studies on human CM showed that brain
capillaries were packed with iRBCs [18]. In the mech-
anical hypothesis, specific interactions between iRBCsl mechanisms underlying clinical progress towards cerebral
M etiology and their typical features: i) the mechanical hypothesis is
ng following anemia, rosette formation and microvascular obstruction;
t increase in vascular permeability, allowing toxic compounds to reach
al hypothesis focuses on the enhanced production by the host of
er soluble factors such as ROS, which are putatively responsible for
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tration of iRBCs within the brain resulting in removal
from peripheral circulation [19-21]. The molecules in-
volved in these interactions are parasite proteins expressed
on iRBC surface, such as P. falciparum erythrocyte mem-
brane protein-1 (PfEMP-1), and specific host receptors
in the microvascular endothelium, including intracel-
lular adhesion molecule-1 (ICAM-1), vascular cellular ad-
hesion molecule-1 (VCAM-1), thrombospondin, CD36, and
E-elastin [22-25].
Cytoadherence and decreased pliability are the main
mechanisms underlying vascular obstruction [9,17-21].
It is speculated that cytoadherence evolved as a mechan-
ism for the parasite to evade triggering a host immune
response and being cleared from the spleen. Cytoadherence
is also beneficial for the parasite as to provide an optimal
environment of low oxygen tension for parasite growth.
Decreased deformability along with increased membrane
stiffness and rigidity of iRBCs are due to changes in the
cytoskeleton triggered by growing intracellular parasites.
Cell deformability has been indicated as a predictor of
anemia development [26], whereas cell rigidity correlates
with a higher fatality rate [27]. Another phenomenon
occurring along with iRBC sequestration is rosetting, char-
acterized by iRBCs forming a flower-like cluster around a
non-iRBC, making a tight rigid structure [28]. Rosetting is
more frequent in patients with CM than in those with un-
complicated malaria. However, rosette formation has also
been reported for other Plasmodium strains (P. vivax and
P. ovale) which do not cause CM [29]. Since rosetting oc-
curs in all manifestations of the disease, it is not associated
with severity or clinical outcome of CM [30]. One question
the mechanical hypothesis by itself does not explain is why
most patients recovering from CM do not show any evi-
dence of ischemic brain damage [12].
Permeability hypothesis
The permeability hypothesis proposes that BBB damage
is the underlying mechanism of CM, such that a leaky
BBB allows toxic compounds to enter the brain and cause
neurological dysfunction [9,13-15,31]. Several animal CM
models have confirmed that the BBB is disrupted and that
cerebral edema is present in CM, although this is less evi-
dent in humans [15]. Nevertheless, iRBCs remain attached
to endothelium, without entering the brain parenchyma
[7,9]. Interestingly, Adams and colleagues have suggested
that iRBC cytoadherence might activate secondary signaling
events similar to those occurring in leukocytes [32]. These
secondary signaling events are thought to cause functional
alterations in the BBB, which could allow toxic compounds
to pass into the CNS. These events might be reversible,
therefore explaining why neurological manifestations are
just transient in most cases and why a large number of re-
covering patients lack neurological sequelae [32].Enwonwu and colleagues implicated histamine as one of
these toxic molecules that enters the brain parenchyma
after BBB impairment and contributes to the neurological
manifestions of CM [33-37]. The authors observed altered
neural histidine uptake in children with severe falciparum
malaria providing an explanation for the enhanced cere-
bral production of histamine [33]. They also found in-
creased plasma levels of histamine in severe malaria
patients, further supporting their hypothesis [34]. More-
over, the involvement of histamine in CM has also re-
cently been confirmed in a murine model [35-37]. In this
study, histidine decarboxylase-deficient mice were unable
to synthesize free histamine and did not develop CM after
infection with P. berghei ANKA. These mice displayed
preserved BBB integrity, were void of iRBC aggregation in
the brain vessels, and did not sequester CD4+ and CD8+
T cells [36]. Further investigation of histamine receptors
revealed histamine-1-receptor (H1R) and histamine-2-
receptor (H2R) are associated with severe malaria devel-
opment [37], whereas histamine-3-receptor (H3R) has a
neuroprotective role [36].
Humoral hypothesis
The humoral hypothesis is a natural extension of the per-
meability hypothesis. This hypothesis suggests that host
factors such as leukocyte-derived cytokines and chemo-
kines can enter the brain parenchyma after increased BBB
permeability, thus causing CM symptoms such as fever
and coma [9,13,14,16,38-40].
Effector cells including T cells, NK cells, and monocytes,
along with inflammatory responses mediated by cytokines
such as tumor necrosis factor-α (TNF-α), limphotoxin-α
(LT-α), and interferon-γ (IFN-γ), are proposed to contrib-
ute to the development of murine CM [41-48]. However,
the extent of their involvement and molecular mecha-
nisms in human CM is still topic of debate [48,49].
CD8+ T cells have been reported to initiate BBB tight
junction disruption and promote CNS vascular permeabil-
ity under neuroinflammatory conditions [50-52]. Consist-
ently, CD8+ T cell sequestration in cerebral microvessels
and subsequent brain infiltration have been demonstrated
in murine CM [43,44], where Plasmodium antigens can
be cross-presented during infection by dendritic cells
(DCs) [53,54] and brain endothelial cells in association
with MHC class I molecules [55]. Recent human studies
support the idea that malaria antigens can be transferred
to endothelial cells [56]. However, it is currently unknown
whether Plasmodium-specific CD8+ T cells are in-
volved in the pathogenesis of human CM [57]. Furthermore,
lymphocyte infiltration into brain parenchyma remains to
be investigated [49].
TNF-α relevance in CM is also unclear. TNF-α involve-
ment in murine CM was first proposed in 1987 [58]. Since
then there have been numerous studies investigating
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ent. For example, some works confirmed the association
of high TNF-α levels with murine CM [59-61], whereas
others argued against such correlation, finding LT-α and
IFN-γ as more suitable markers [44,47,62,63]. To recon-
cile such discrepancies, it has been proposed that low con-
centrations of TNF-α could enhance parasite killing,
whereas higher concentrations might be associated with
increased incidence of murine CM [46]. However, data on
TNF-α also appear inconclusive in human CM studies.
Indeed, clinical studies tend to exclude any association
between CM and increased plasma, serum or CSF levels
of TNF-α [64-67], although a few works have proposed a
correlation in two different Asian populations [68,69].
Instead, in some of these studies, high CXCL10/IP-10
plasma levels and low angiogenic factors such as vas-
cular endothelial growth factor (VEGF) and angiopoietin-
1 (Ang-1) in children with CM, predicted subsequent
mortality [65,66,68]. Moreover, a protective role for IL-12
has been proposed in human CM [70,71].
Among soluble factors involved in CM, a critical role
for nitric oxide (NO) has also been suggested. It was hy-
pothesized that NO levels correlate with disease severity,
since the sequestration of iRBCs might contribute to CM
pathogenesis by causing hypoxia, which is related to en-
hanced production of cytokine-induced NO, compensa-
tory vasodilatation, and subsequent brain volume increase
[39]. However, activation of inducible NO synthase (NOS)
might also serve protective functions, since NOS inhibits
the side effects of brain indoleamine 2,3-dioxygenase
(IDO) and quinolinic acid accumulation [72], although
IDO systemic distribution is independent of malaria dis-
ease severity [73]. In a study performed on Tanzanian
children infected with malaria, the plasma levels of NOS-
suppressing IL-10 increased with disease severity, suggest-
ing that a reduced NO production may contribute to CM
[74]. Moreover, a genetic single nucleotide polymorphism
found in the NOS2 promoter region causes elevated NO
production and was significantly associated with protec-
tion against CM in Tanzanian and Kenyan children [75].
In line with these observations, Anstey and colleagues
demonstrated that decreased NO production was associ-
ated with endothelial dysfunction in human CM [76,77].
Similarly, van der Heyde and his group demonstrated
that low NO bioavailability was associated with mur-
ine CM [78,79]. Interestingly, prophylaxis with inhaled
NO in CM-sensitive mice significantly reduced systemic
inflammation and endothelial activation by lowering
TNF-α, IFN-γ, monocyte chemotactic protein-1 (MCP-1),
sICAM-1 and von Willebrand factor, and by increasing
Ang-1 levels in peripheral blood [80]. The protective
effect of exogenous NO on mouse CM appears asso-
ciated with decreased brain vascular expression of in-
flammatory markers, resulting in attenuated endothelialjunction damage and facilitating blood flow [81]. Lastly,
treatment with exogenous L-arginine, the substrate for
NOS, recently proved to be safe in a pilot study on CM
patients, although effective doses still need to be opti-
mized [82].
Furthermore, during malaria infection both host and
parasite undergo strong oxidative stress, which leads to in-
creased production of reactive oxygen species (ROS) and
subsequent protein and lipid peroxidation [83,84]. The co-
existence of both parasite and erythrocyte is a matter of a
delicate balance: low ROS concentrations seem to inhibit
parasite growth, whereas larger amounts may damage vas-
cular endothelial cells and increase vascular permeability
[85]. Oxidative stress paradoxically has both a pathogenic
and protective role in CM [86]. An anti-oxidant diet was
shown to reduce BBB damage and counteract CM devel-
opment in CM-sensitive mice [87], and anti-oxidant adju-
vant therapy, provided at the initial stages of murine CM,
prevented the development of persistent cognitive damage
[88]. In contrast, NADPH-deficient mice were shown
to develop CM despite the lack of ROS production,
suggesting that ROS did not contribute to CM pathogen-
esis [89,90]. To reconcile such an apparent inconsistency,
Linares and colleagues have recently shown that glutathi-
one peroxidase and heme oxygenase-1 up-regulation co-
operate to suppress superoxide dismutase, catalase, heat
shock protein-70 and thioredoxin-1 down-regulation ef-
fects in murine CM, counteracting oxidative damage and
maintaining redox equilibrium [91]. In human CM, ROS
have been associated with a pathogenic role thus far. In
vitro, ROS inhibition was shown to protect brain endothe-
lial cells against P. falciparum-induced apoptosis and to
decrease iRBC cytoadherence through ICAM-1 down-
regulation and iNOS induction [92,93]. Consistently, in a
recent clinical study performed on fifty Indian children
with severe malaria, oxidative stress was associated with
disease severity [94].
Blood–brain barrier impairment in cerebral malaria
The BBB is one of three main barrier defences protecting
the CNS. It is constituted of cerebral vascular endothelial
cells, which do not form a rigid structure, but rather
a dynamic interface with a range of physical, biochemical
and immune properties and functions, built from effective
inter-cellular junctions and cell-matrix adhesion mole-
cules, enzymes, and trans-endothelial transport systems
[95]. In particular, BBB integrity is dictated by tight junc-
tions between adjacent endothelial cells, forming a network
of strands composed by several proteins, including junc-
tional adhesion molecules, claudins (mainly -1 and -5) and
occludin, which interact with cellular actin through cyto-
plasmic proteins such as zonula occludens-1 (ZO-1) [96].
Figure 2 depicts the structure of neural inter-endothelial
tight junctions, along with cell-matrix adhesion complexes
Figure 2 Blood–brain barrier structure: cerebral microvascular inter-endothelial junctions (adherens and tight junctions) and
cell-matrix adhesion molecules. Diagram showing the structures of CNS inter-endothelial junctions, including adherens junctions and tight
junctions, and of cell-matrix adhesion complexes, including talin, filamin, tensin or α-actinin filaments associated with integrins in the extracellular
matrix. The core of adherens junctions results after the interactions among transmembrane glycoproteins, such as VE-cadherin, whose cytoplasmic
face is linked to the catenin family members, including p120-catenin, β-catenin, and α-catenin. Tight junctions are composed of a branching
network of sealing strands, each of which is formed by extracellular domains of transmembrane proteins, claudins and occludin, joining one
another directly. These transmembrane proteins associate with different peripheral membrane proteins such as ZO-1 located on the intracellular
side of plasma membrane, anchoring the strands to the actin component of the cytoskeleton.
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associated with integrins. We will next discuss how
the disruption of these molecules by host proteolytic en-
zymes such as MMPs could play a relevant role in CM
pathophysiology.
BBB functional integrity and permeability are generally
assessed by evaluating the passage of molecules from the
blood into the cerebral-spinal fluid (CSF). BBB perme-
ability is determined by size and charge of the molecules,
and the presence of specific BBB receptors to aid in the
transport of certain molecules. The importance of BBB
physiology and pathology has led to the development of
several BBB models to better investigate the physio-
logical, anatomical and functional characteristics [97].
However, once again the current experimental data onBBB status during CM are high variable among different
model systems [98].
Phenotype of brain and non-brain endothelial cells
co-cultured with Plasmodium iRBCs in vitro
As discussed below and summarized in Table 1, evidence
showing differential phenotypes between neural and non-
neural endothelial cells after co-culture with Plasmodium
iRBCs comes from several in vitro studies [56,93,99-108].
First, the effects of P. falciparum infection were inves-
tigated in a BBB model of cultured primary porcine brain
capillary endothelial cells (PBCECs) [99]. In this study,
membrane-associated malaria antigens obtained from
lysed P. falciparum schizont-iRBCs increased endothelial
E-selectin and ICAM-1 expression, reduced the trans-
Table 1 Phenotype of endothelial cells after co-culture with infected red blood cells in vitro
Endothelial cell type Plasmodium strain Evaluated parameters Endothelial phenotype Ref.
Porcine brain capillary endothelial cells (PBCEC) P. falciparum - ICAM-1, E-selectin expression; - increased ICAM-1 and E-selectin [99]
- TEER; - decreased BBB function;
- tight junction expression - tight junction disruption
Human umbilical vascular endothelial cells (HUVEC) co-cultured
with iRBC-fed peripheral blood mononuclear cells
P. falciparum from patients
with uncomplicated malaria,
severe malaria, or CM
mRNA expression of: - increased adhesion molecule mRNA (not CM-specific); [100]
- adhesion molecules
(ICAM-1, VCAM-1, E-selectin);
- reduced tight junction mRNA (CM-specific)
- tight junctions
(occludin, vinculin, ZO-1)
TNF-α- or LT-α-activated human brain endothelial cell line
(HBEC-5i) (with/without platelet co-culture)
P. falciparum - permeability to 70-kDa dextran; - increased BBB permeability; [101]
- TEER; - decreased BBB function;
- endothelial microparticle release; - increased microparticle release;
- endothelial apoptosis - increased endothelial apoptosis (all effects potentiated
by platelets)
Human brain microvascular endothelial cells (HBMEC); HUVEC P. falciparum - ICAM-1 expression increased ICAM-1 expression in HBMEC but not in
HUVEC
[93]
HBMEC P. falciparum - electrical cell substrate sensing; - reduced BBB function; [102]
- TEER - increased BBB permeability
Human dermal microvascular endothelial cells (HDMEC);
human lung microvascular endothelial cells (HLMEC)
(with parasite sonicates or iRBCs)
P. falciparum - immunofluorescence staining of
ZO-1, claudin-5, VE-cadherin;
- loss in total protein content of claudin-5; [103]
- observation of inter-endothelial
gaps in monolayers;
- redistribution of ZO-1 from cytoskeleton to membrane
and cytosolic/nuclear fractions;
- evaluation of pro-inflammatory
response, direct cellular cytotoxicity
or cell death.
- minimal inflammation and death (all effects only with
sonicates)
HBMEC P. falciparum - expression of transcriptome
(including ICAM-1 and
pro-inflammatory molecules)
- increased expression of ICAM-1 and pro-inflammatory
molecules
[104]
HBEC-5i; immortalized human cerebral microvascular cell
line hCMEC/D3
P. falciparum - immunofluorescent microscopy to
evaluate malaria antigen
presentation by endothelial cells;
- malaria antigen presentation by endothelial cells; [56]
- tight junction opening;
- TEER - increased BBB permeability
hCMEC/D3 P. falciparum - fluorescent permeability assay; - increased BBB permeability; [105]
- expression of cell adhesion
molecules and tight junctions
- increased ICAM-1 expression;
- cytoadherence;
- altered ZO-1 distribution
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Table 1 Phenotype of endothelial cells after co-culture with infected red blood cells in vitro (Continued)
TNF-α-activated subcutaneous fat tissue-derived EC from
patients with uncomplicated malaria or CM
P. falciparum - adhesion molecule expression
(ICAM-1, VCAM-1, CD61, CD62-E)
- higher ICAM-1, VCAM-1, CD61; [106]
- enhanced microparticle release;
- microparticle production;
- induced MCP-1 and IL-6 release;
- MCP-1, RANTES, IL-6 release ; - higher caspase-3 activation (all effects CM-specific)
- caspase-3 activation
HBEC-5i P. falciparum (various strains) parasite strain selection assay based
on cytoadherence
CM-associated cytoadherence [107]
Murine brain vascular endothelial cells (MBVEC) murine
lung vascular endothelial cells (MLVEC)
P. berghei ANKA (CM model);
P. berghei K173
(non-CM model)
- study of cytoadherence
mechanisms;
higher VCAM-1-mediated cytoadherence in CM model
compared to non-CM model
[108]
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disruption of tight junctions, indicative of increased BBB
permeability.
Consistently in various types of human brain endothe-
lium, including HMBEC primary cultures and HBEC-5i
or hCMEC/D3 cell lines, iRBCs were also shown to
increase ICAM-1 expression [93,99,104,105], to reduce
TEER [56,101,102], to alter tight junction expression and
distribution [56,105], and to enhance BBB permeabil-
ity to 70-kDa dextran [101]. Interestingly, platelets were
suggested to play a key role in iRBC-dependent in-
crease in BBB permeability, releasing microparticles and
causing cell apoptosis in TNF-α- and LT-α-activated
HBEC-5i [101]. In hCMEC/D3 cells, iRBC-increased cell
adhesion and paracellular permeability correlated with
ZO-1 disorganization, but the latter effect appeared medi-
ated by parasite-induced metabolic acidosis, independent
from cytoadherence [105]. Moreover, differential global
gene expression in HBMEC after interacting with iRBCs
revealed significantly up-regulated transcripts related to
immune and inflammatory responses, apoptosis, cell-
cell signaling, signal transduction and nuclear factor-
kB (NF-kB)-activation cascade [104]. After co-culturing
with iRBCs, the mRNA expression of neural endothelial pro-
inflammatory chemokines (IL-6, CXCL-8/IL-8, CXCL-1/
GRO-α, CXCL-2/MIP-2α, and CCL-20/MIP-3α) increased
more than 100-fold, highlighting the strong inflamma-
tory component and the active role of the endothelium in
CM pathogenesis [104]. Furthermore, in TNF-α-activated
subcutaneous fat tissue-derived endothelial cells, a model
comparable to cerebral endothelium, P. falciparum
iRBCs induced several CM-specific effects, including
up-regulation of ICAM-1, VCAM-1, and CD61, en-
hancement of microparticle, MCP-1 and IL-6 release,
and higher caspase-3 activation [106]. Increased levels of
inflammatory cytokines may have direct systemic effects
and adversely affect the clinical outcome by increasing the
cytoadherence of infected RBCs to venular endothelium
through up-regulation of adhesion molecules, such as
ICAM-1 [93].
To assess the specificity of these effects for human
cerebral endothelium, additional comparative studies
were also performed using non-neural endothelial cells.
Interestingly, P. falciparum iRBCs did not affect the ex-
pression and distribution of tight junctions (as measured by
claudin-5 and ZO-1) and did not induce pro-inflammatory
response or cell death in human dermal or lung micro-
vascular endothelium, although parasite sonicates did [103].
Additionally, the up-regulating effects of iRBCs on ICAM-1
expression observed in HBMEC were not reproduced in
human umbilical vascular endothelial cells (HUVEC) from
healthy donors [93]. An increase in ICAM-1, VCAM-1,
and E-selectin mRNA was found in HUVEC from patients
with different degrees of malaria (uncomplicated, severe, orCM) after co-culturing with iRBC-fed mononuclear cells,
however such increase did not appear specific for CM. On
the contrary, reduced mRNA levels of tight junction pro-
teins (occludin, vinculin, and ZO-1) were strictly associated
with CM [100].
Genetic differences between Plasmodium strains might
also play a role in CM development. Indeed, it has been
shown that different strains of P. falciparum display variable
degrees of cytoadherence to HBEC-5i [107]. Additionally,
P. berghei ANKA, a murine CM-associated Plasmodium
strain, induces a higher VCAM-1-mediated cytoadherence
compared to P. berghei K173 (non-CM strain) in either
brain or lung mouse vascular endothelial cells [108].
Blood–brain barrier and in vivo animal models of cerebral
malaria
Several in vivo animal models have reported alterations
in BBB after exposure to Plasmodium parasites or mal-
aria products such as hemozoin (Hz, malarial pigment)
[47,109-124]. As summarized in Table 2 and described
below, these studies provide insightful findings regarding
BBB breakdown in animal CM models.
The first animal studies on BBB permeability in mal-
aria date back to 1968, when Migasena and Maegraith
demonstrated the movement of albumin across the BBB
in Macaca mulatta monkeys infected with P. knowlesi
[109-111]. However, P. knowlesi does not induce CM. As
such, the rhesus monkey infected with primate malaria
parasites, P. coatneyi and P. fragile, is considered to be a
more valid primate model to study in the context of se-
vere malaria with cerebral involvement [112-114].
Of the four species of rodent malaria parasites (P. berghei,
P. yoelii, P. chabaudi, P. vinckei), only a few P. berghei strains
can induce experimental CM in mice, with the ANKA strain
being the most widely studied. Symptoms of experimental
CM in P. berghei ANKA-infected susceptible mice include
paralysis, ataxia, head deviation, convulsion and coma
[98]. In P. berghei K173-infected mice an excessive move-
ment of water, albumin and other proteins into the brain,
as well as severe brain edema, microthrombosis, sludging
of mononuclear cells, arteriolar spasms, scattered distur-
bances of the microcirculation, and occasional prolifera-
tion of gliocytes were observed, suggesting a progressive
deterioration of BBB integrity culminating in endothelial
lesions and haemorrhages [31,115-118]. Of note, mouse
CM models present neurological signs (ataxia, hemiplegia
and coma) similar to the clinical features reported in hu-
man CM [119].
In a recent work, Penet and colleagues presented the
first in vivo magnetic resonance study of mouse CM,
demonstrating BBB breakdown in CM. Multimodal mag-
netic resonance neuroimaging techniques (imaging, diffu-
sion, perfusion, angiography, spectroscopy) of P. berghei
ANKA-infected mice revealed vascular damage, including
Table 2 Evidence of blood–brain barrier (BBB) impairment in animal models with cerebral malaria (CM)
Animal source Plasmodium
strain
Method to evaluate BBB integrity Degree of impairment Reference
Rhesus monkey
(Macaca mulatta)
P. knowlesi Examination of movement of proteins
across the BBB by radiometric and
fluorimetric methods
Increase of BBB permeability [109-111]
Rhesus monkey
(Macaca mulatta)
P. fragile Electron microscopy, immunohistochemical
analysis (CD36, thrombospondin, ICAM-1),
formation of rosettes
Parasitized red blood cells sequestration
and adherence to endothelial cells in
the cerebral microvessels, neurological
symptoms similar to humans
[112]
Rhesus monkey
(Macaca mulatta)
P. coatneyi Clinical observation Anemia, coagulopathy, and renal and
metabolic dysfunction
[113]
Rhesus monkey
(Macaca mulatta)
P. coatneyi Tissue samples from the brain (cortex and
white matter of the cerebrum, cerebellum,
and midbrain) collected for quantitation of
mRNA expression of cytokines, adhesion
molecules, and iNOS
Expression of pro-inflammatory and T
helper-1 cytokines, adhesion molecules,
and iNOS appears to predominate in the
cerebellum of infected rhesus monkeys
[114]
A/J and CBA/H mice P. berghei (ANKA) Detection of the movement of the dye
Evans blue, radioisotope labelled albumin
and erythrocytes
Breakdown of BBB [115]
mouse P. berghei (K173) Histochemical and histological evaluation of
cerebral lesions and their distribution
Progressive deterioration of BBB integrity [116-118]
CBA/T6, Balb/c
and DBA/2 J mice
P. berghei
(ANKA and K173)
Evaluation of neurological signs
(ataxia, hemiplegia and coma)
Increased permeability of BBB [119]
Mouse P. berghei (ANKA) Multimodal magnetic resonance techniques
(imaging, diffusion, perfusion, angiography,
spectroscopy).
BBB breakdown [120]
CM- resistant BALB/c mice P. berghei (ANKA) Evaluation of pro-inflammatory cytokines
produced
BBB breakdown [121]
C57BL/6 and BALB/c mice P. berghei (NK65) Histopathological analysis of cerebral tissue Increased permeability of BBB [122]
TNF-α-and
LT-α-deficient mice
P. berghei (ANKA) Histochemical and histological evaluation Neurological signs of CM, associated
with perivascular brain haemorrhage in
TNF-α -/- mice; completely resistant to
CM in LT-α -/- mice
[47]
Mouse P. berghei (ANKA) Examination of the outcome of TGF-β and
TNF-α production in the context of
splenocyte apoptosis
Critical balance between TGF-β and
TNF-α might have a key role in BBB
breakdown
[123]
Different murine models:
CBA/CaJ and Swiss Webster
mice (CM sensitive), Balb/c
and A/J mice (CM resistant)
P. berghei (ANKA)
P. yoelii (17XL)
P. berghei (NK65)
and P. yoelii (YM)
Examination of histopathological alterations,
BBB dysfunction, or neurological signs
CM related to the opening of
paracellular-junctional and transcellular-
vesicular fluid transport pathways at the
neuroimmunological BBB
[124]
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tion, reduced brain perfusion and ischemic metabolic pro-
file, with reduced high-energy phosphates and enhanced
brain lactate. These data strongly point to the coexistence
of inflammatory response and ischemic lesions [120].
Other recent works illustrated a complex strain-dependent
relationship between leukocyte recruitment, BBB perme-
ability and chemokine production. Major pathological con-
sequences of malaria arise from inappropriate or excessive
immune response mounted by the host in an attempt to
eliminate the parasite. In P. berghei ANKA-infected
mice, inflammation of the cerebral microvasculature and
leukocyte recruitment were clearly evident and found to
be driven by production of pro-inflammatory cytokines
(IL-12, IFN-γ) and CM development [121]. On the otherhand, P. berghei NK65-infected mice showed enhanced pro-
duction of LT-α and several chemokines (CXCL-9/MIG,
CCL-2/MCP-1, CCL-3/MIP-1α and CCL-5/RANTES), but
no neurological symptoms [47,122]. A complementary study
performed on the same model proposed a concurrent role
for Transforming Growth Factor-β (TGF-β) and TNF-α in
promoting splenocyte apoptosis [123].
It should be noted that the cerebral microvascular tree
contains two functionally distinct BBB: i) the physio-
logical BBB, formed by capillaries 4–8 mm in diameter,
consisting of a single layer of endothelia, gliovascular mem-
brane, and astrocyte endfeet; and ii) the neuroimmunologi-
cal BBB, formed by postcapillary venules 10–60 mm in
diameter and encompassing two layers - the endothelium
with its basement membrane and the glia limitans with
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space [125]. The physiological BBB serves as a tight diffu-
sion barrier for small solutes while the neuroimmunological
BBB permits transport of macromolecules and diapedesis
of immune cells [125]. In a very recent study comparing
different mouse models of experimental CM (P. berghei
ANKA infection), human CM-like histopathology (P. yoelii
17XL) and non-CM (P. berghei NK65 and P. yoelii YM),
Nacer and colleagues observed that the physiological
BBB in the experimental CM model remained intact,
whereas regulated fluid transport across the neuroimmu-
nological BBB led to brain swelling, intracranial hyperten-
sion, coma, and ultimately death due to dysfunction of
respiratory centers in pons and the medulla oblongata as a
result of brain stem compression [124]. Thus, they pro-
posed that CM may occur in two steps: 1) induction of
coma based on regulated, preventable and reversible
opening of the neuroimmunological BBB; and 2) endothe-
lial death-associated haemorrhaging, which is difficult to
reverse by treatment and eventually fatal [124]. A similar
mechanism for neuroimmunological BBB opening in hu-
man CM would explain the reversibility of coma with
treatment, the scarce traces of tissue necrosis in surviving
patients, and the different neurological outcomes of pa-
tients despite similar clinical presentation [6,8,9,13,102].
Blood–brain barrier and human studies on cerebral malaria
BBB functional impairment during human CM has been
investigated in several clinical and post mortem studies
[126-143]. Table 3 summarizes the most relevant results.
Here, the investigations on human CM patients were
performed using albumin CSF/serum ratio as an indica-
tor of BBB integrity [126-128], by post mortem immuno-
histochemical analysis [129-135], or through brain imaging
techniques [136-144]. Interestingly, the BBB seems to be
more impaired in children than in adults. Moreover, it ap-
pears that African and Asian patients display a different
degree of BBB damage, with BBB breakdown being more
likely to occur in African than Asian populations.
One of the first studies on Asian patients was conducted
in Thailand [126]. In this work, albumin CSF/serum ratios
were higher in CM patients than in controls, but it did
not correlate with coma and mortality. Thus, the authors
concluded that their data did not support the idea that
cerebral edema might be the cause of coma. More than a
decade later, albumin and Immunoglobulins G plasma/
CSF ratios were found to be only mildly impaired in
Vietnamese patients, suggesting only minimal degree of
BBB breakdown in few CM cases [127]. Therein, human
CM appeared to cause only subtle functional changes in
BBB integrity, with minimal intra-parenchymal inflamma-
tory response compared with other neurologic infections,
such as cryptococcal, tubercular, and acute bacterial men-
ingitis [127].Regarding African populations, a study on Zairean chil-
dren showed no difference in CSF albumin compared to
controls [128]. However, in Malawian children with CM,
the activation of endothelial cells and macrophages, along
with the disruption of endothelial intercellular junctions
in vessels containing sequestered iRBCs, and subtle but
measurable changes in albumin CSF versus albumin serum
levels were observed. Nevertheless, negligible leakage of
plasma proteins was still apparent [129]. In Kenyan chil-
dren with CM, protein and amino acid levels in paired
plasma and CSF samples were measured, showing that
BBB was mildly impaired in some children with severe
falciparum malaria [130]. However, this impairment was
not confined to CM, as it was also reported in children with
prostration-associated malaria and, to a lesser extent, in
children with malaria and seizures. Evidence of intrathecal
immunoglobulin synthesis in children with malaria was also
observed [130]. Finally, data obtained in a recent work per-
formed on Malawian children are consistent with the pro-
posed link between iRBCs sequestration and intravascular/
perivascular pathology in fatal pediatric CM, resulting in
myelin damage, axonal injury, and BBB breakdown; how-
ever, no Hz-laden monocyte extravasation was found [131].
Pathological studies on post mortem samples of CM
patients showed cerebral edema and raised intracranial
pressure in 50% of West African children [132] but not
in South Asian adults [133,134] or Malawian children
[129]. Nevertheless, an important correlation between
sequestration of iRBCs in the brain microvessels and the
malaria-related encephalopathy was shown in Asian pa-
tients [133]. The adhesion of iRBCs to brain microvessels
is mediated by specific receptors on the host endothelium,
including ICAM-1, CD36 and CD31 [22-25]. Immunohis-
tochemistry showed altered distribution of the cell junc-
tion proteins occludin, vinculin and ZO-1 in Vietnamese
adults and Malawian children with CM [129,135]. Seques-
tration of iRBCs in cerebral microvessels was significantly
higher in the brains of patients with CM compared with
non-CM patients in all parts of the brain (cerebrum, cere-
bellum, and medulla oblongata), and was quantitatively as-
sociated with pre mortem coma [129].
In recent years, several imaging studies have been also
conducted on the brains of CM patients during disease pro-
gress or after recovery [136-144]. Using magnetic resonance
or computed tomography, several common features impli-
cating BBB damage have been observed, including cerebral
edema, increased brain volume, ischemia and large vessel
infarcts, hemorrhagic cortical lesions, focal and multifocal
atrophy, and limited CSF circulation [136-139,141-144].
Interestingly, magnetic resonance in a recently published
case-report of a 37-year-old French patient with malaria
travelling back from Equatorial Guinea, showed that he
developed posterior reversible encephalopathy syndrome,
which is characterized by diffuse symmetric signal-intensity
Table 3 Evidence of blood–brain barrier (BBB) impairment in human cerebral malaria (CM) patients
Group type Plasmodium
strain
Number of
patients per
cohort
Method to evaluate BBB integrity Degree of impairment Reference
Thai patients P. falciparum 157 Albumin CSF/serum ratio BBB intact [126]
Vietnamese patients P. falciparum 20 Albumin and Immunoglobulins G
plasma/CSF ratios
Minimal BBB breakdown in a few
cases of CM
[127]
Zairean children P. falciparum 21 Albumin CSF/serum ratio BBB not impaired [128]
Malawian children P. falciparum 72 Immunohistochemistry on autopsy
brain tissues
Disruption of endothelial intercellular
junctions and impaired BBB function
[129]
Kenyan children P. falciparum 100 Protein and immunoglobulin CSF/
serum ratio
Mild BBB impairment in some cases [130]
Malawian children P. falciparum 50 Immunohistochemistry on autopsy
brain tissues
BBB breakdown [131]
Nigerian children P. falciparum 61 Examination of the possible risk
factors for poor prognosis and
studies on post mortem samples
Cerebral edema and raised
intracranial pressure in 50%
[132]
Thai and Vietnamese
children
P. falciparum 65 Studies on post mortem samples Cerebral sequestration of
P. falciparum-infected erythrocytes
[133]
Vietnamese patients P. falciparum 20 Studies on post mortem samples Heterogeneous cerebral edema
and plasma protein leakage
[134]
Vietnamese adults
and Malawian
children
P. falciparum 14 Immunohistochemistry Alteration of cell junction proteins
occludin, vinculin and ZO-1
[135]
Kenyan children P. falciparum 14 Computed tomography Cerebral edema and ischemia [136]
French adults back
from Cameroon,
Niger, and Thailand
P. falciparum 3 Magnetic resonance Hemorrhagic cortical lesions [137]
Malian children P. falciparum 8 Computed tomography Diffuse atrophy with asymmetrical ventricle
dilation, suggesting limited CSF circulation
[138]
French adult back
from Equatorial
Guinea
P. falciparum 1 Magnetic resonance BBB breakdown [140]
Malawian children P. falciparum 14 Computed tomography Fatal CM: cerebral edema, large vessel
infarcts; Non fatal CM with neurological
sequelae: focal/multifocal atrophy
[141]
Indian adults P. falciparum 4 Magnetic resonance Bithalamic infarctions with or
without haemorrages
[142]
Malawian children P. falciparum 120 Magnetic resonance increased brain volume; abnormalities
in cortical, deep gray, and white
matter structures
[143]
Malawian children P. falciparum 38 Magnetic resonance periventricular and subcorical T2 signal
changes, atrophy, and focal cortical defects
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tion territory [140]. Since data from previous litera-
ture suggest one of the mechanisms of posterior reversible
encephalopathy involves capillary leakage and acute
disruption of the BBB, the authors concluded that this
case-report supports the theory of BBB disruption as a key
factor for CM development [140].
Blood–brain barrier impairment in cerebral malaria: some
reflections upon the available studies
Clearly there is much discrepancy on the extent of BBB
damage between animal and human models of CM. Whileseveral studies performed on mouse CM models suggest a
strong BBB breakdown [115-124], data on increased BBB
permeability in human CM are somehow less evident,
generally suggesting the occurrence of only mild BBB im-
pairment, characterized by a relevant degree of tight junc-
tion disruption, but lacking molecule exchange between
serum and CSF [126-135].
In this context, it should be noted that the relevance
of murine CM models for studying CM pathophysiology
has been a topic of big debate in the recent years [49].
Being clearly an inflammatory syndrome with local vas-
cular endothelial activation, murine CM displays obvious
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pathological features of human CM, such as signs of
vascular inflammation/damage [145]. A recurring issue
concerns the degree of iRBC sequestration in the brain
and other organs of P. berghei ANKA–infected mice. Al-
though recent data find increased iRBC accumulation
during murine CM in multiple organs including the
brain [146], P. berghei infection is generally acknowledged to
promote marked accumulation of leukocytes (particularly
monocyte, macrophages and T cells), which is in stark con-
trast to human CM [147]. Thus, despite several processes
shared either by murine or human CM, the changes in the
endothelial cell microenvironment induced by cytoadher-
ence and inflammation are not the same [104]. Addition-
ally, mouse studies suggesting associations between high
levels of cytokines and CM [58-61] have been recently
challenged by works showing that high levels of pro-
inflammatory cytokines such as TNF-α are poor indicators
of human CM in African children [64-67]. Thus, future
experimental studies on alternative animal models (non-
human primates and other mouse models) are encouraged
and urgently necessary to better understand the patho-
logical processes underlying human infection [49].
Another interesting point emerging from clinical data
is that the BBB appears more impaired in children than
in adults [126-143]. Since CM often strikes children at a
critical time in brain development, Hawkes and col-
leagues have nicely hypothesized that developmental
changes in the cerebral vasculature may account for
some of the differences in disease presentation and out-
come between children and adults, including mortality,
seizures and neurocognitive sequelae, rates of associated
anemia and renal dysfunction, retinal vessel changes,
frequency of ring haemorrhages, and inflammatory cell
accumulation in brain microvessels [148]. To avoid any
misunderstanding, it has been pointed out that the wide-
spread belief amongst neurotoxicologists that BBB is im-
mature or even absent in the newborn is contrasted by a
substantial body of evidence supporting the concept of
well-developed barrier mechanisms in the developing
brain [149,150]. For instance, inter-cellular tight junc-
tions between cerebral endothelial cells and between
choroid plexus epithelial cells are functionally effective
as soon as they differentiate [150]. Nevertheless, the brain
develops within an environment that is different from that
of the rest of the body, and the developing brain possesses
a number of unique features not generally present in the
adult [149]. Interestingly, certain genes coding for influx/
efflux proteins are expressed at much higher levels early
in development than in the adult, and there is physio-
logical evidence that these transport systems are function-
ally more active in the developing brain [150]. How such
differences between the pediatric and adult BBB can
affect CM pathogenesis and correlate with enhancedBBB permeability in pediatric CM is still unknown. Future
research aimed at shedding light on this topic will cer-
tainly be useful.
Involvement of matrix metalloproteinases in cerebral
malaria
In the last decade, experimental evidence implicated a spe-
cific family of host proteolytic enzymes known as MMPs
in malaria pathogenesis [2,151-154]. MMPs are either se-
creted or membrane-bound zinc-dependent proteases, and
their role is also related to the inflammatory response and
the BBB function [155-163]. Members of the MMP family
are produced by a broad spectrum of specialized cells, in-
cluding fibroblasts, endothelial cells, lymphocytes, mono-
cytes, macrophages, smooth muscle cells, glial cells, and
neurons [155,158].
As detailed in Figure 3, the mammalian MMP family
encompasses 25 members, categorized by different num-
bers or named depending on their matrix substrates.
MMPs are evolutionarily conserved and tightly regu-
lated. Conserved protein domains include an N-terminal
signal peptide required for secretion, a cleavable pro-
domain maintaining enzymatic latency, a catalytic domain,
a Zn-binding domain, and (besides the minimal MMPs) a
C-terminal hemopexin domain thought to be important
for protein-protein interactions [155,157,160,162,163].
The active domain and the Zn-binding domain are essen-
tial for catalytic activity: upon pro-domain cleavage a
Zn2+-ion becomes available to coordinate with a hydrolytic
water molecule to enable nucleophilic attack of a substrate,
and the enzyme is functionally active [164]. Additional
MMP motifs include a gelatin-binding fibronectin-like do-
main, a serine-, threonine- and proline-rich collagen type
V-like domain, a C-terminal transmembrane (TM) domain
or GPI anchor, and in some cases a cytoplasmic domain
[155,157,160,162,163]. MMP-2 and MMP-9 (also named
gelatinase A and B) are further characterized by the pres-
ence of three head-to-tail cysteine-rich repeats within
the catalytic domain reminiscent of the collagen-binding
type II repeats of fibronectin and this domain is necessary
for the binding and cleaving activities of these MMPs
[161,165,166]. Six membrane-anchored MMPs (MT1-
to MT6-MMPs) have a basic RX(K/R)R motif at the
C-terminal end of their pro-domains. This motif is recog-
nized and cleaved intracellularly by furin-like proteases.
Four MT-MMPs (MT1- to MT4-MMPs) are anchored to
the cell membrane through a type I TM domain while the
other two MT-MMPs (MT5- and MT6-MMPs) are teth-
ered to the membrane via a GPI moiety. An additional
MT-MMP (MMP-23) has an N-terminal type II TM do-
main [162].
MMPs are regulated at multiple levels including transcrip-
tion, translation, compartmentalization, secretion, activation,
and inhibition by protein inhibitors. Most MMPs are found
Figure 3 Nomenclature and structure of mammalian matrix metalloproteinases(MMPs). The mammalian MMP family encompasses 25
members, categorized by different numbers (standard MMP nomenclature) or named depending on their matrix substrates (enzyme nomenclature).
Each MMP displays some conserved structural domains, including: i) an N-terminal signal peptide required for secretion; ii) a cleavable pro-domain
maintaining enzymatic latency; iii) a catalytic and Zn-binding domain; and iv) a C-terminal hemopexin domain. Optional MMP motifs include a
fibronectin-type domain, a vitronectin motif, a furine cleavage site, three head-to-tail cysteine-rich repeats, and (for MT-MMPs) a
C-terminal transmembrane domain or GPI anchor occasionally associated with a cytoplasmic domain.
Polimeni and Prato Fluids and Barriers of the CNS 2014, 11:1 Page 13 of 24
http://www.fluidsbarrierscns.com/content/11/1/1at low levels and not constitutively transcribed, but are
expressed after external induction by pro-inflammatory
molecules, growth factors, NO, cell-cell interactions, cell-
matrix interactions, UV radiations [155,157,159-162]. Sev-
eral signalling pathways and transcription factors are
known to regulate MMP expression, including mitogen-
activated protein kinases (MAPKs), NF-kB, and activator
protein-1 (AP-1) [155,165,167]. After synthesis, MMPs are
stored in inflammatory cell granules, which restrict their ac-
tion [161]. Furthermore, MMPs are produced as inactive
zymogens, referred to as pro-MMPs. Activation is achieved
by various proteases (other activated MMPs and several
serine proteases) or ROS that disrupt the interaction be-
tween the active site zinc atom in the catalytic domain
and the conserved cysteine within the pro-domain. Pro-
MMPs can be cleaved and activated through different mech-
anisms and in a context-specific manner. For example,pro-MMP-9 is activated through a proteolytic cascade
sequentially involving plasminogen, MMP-3 and MMP-1
[165]. The activation of proMMP-2 requires previous forma-
tion of a pro-MMP-2/tissue inhibitor of metalloproteinase-2
(TIMP-2)/MT1-MMP (MMP-14) multimeric complex
[166]. In addition to pro-MMP-2 activation, the bind-
ing of TIMP-2 to MT-1-MMP and MT-3-MMP slows
down the autocatalytic turnover of these MT-MMPs, para-
doxically enhancing surface proteolysis further by stabiliz-
ing the pool of active enzyme at the cell surface [160,168].
Once MMPs have been released into the extracellular
space or anchored to the membrane and activated, they
are kept in check by their endogenous tissue inhibitors
(four different forms, from TIMP-1 to TIMP-4). TIMPs
inhibit MMP activity with relatively low selectivity in a 1:1
stoichiometric ratio. Interestingly, the ratio of MMP:TIMP
can also influence activation mechanisms [157,167].
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responsible for tail resorption during frog metamorphosis.
Thus, they were first characterized as proteases involved in
degrading structural proteins comprising the extracellular
matrix (ECM) and sub-endothelial basement membranes
[155]. However, MMPs are now known to have more so-
phisticated processes than mere ECM turnover. MMPs
can also cleave a growing spectrum of other substrates, in-
cluding cytokines, chemokines, growth factors, hormones,
chemotactic and adhesion molecules, membrane recep-
tors, intercellular junctions, as well as other proteases, in-
cluding some hemostasis-related molecules and MMPs
themselves, protease inhibitors, clotting factors, and anti-
microbial peptides [169-171]. MMP-dependent cleavage
can serve to activate, inhibit, process, release, shed, or re-
veal cryptic codes in the substrates they act on. Therefore,
the once formidable proteolytic potential of MMPs is now
realized to serve essential roles in promoting or inhibiting
cell survival, proliferation, migration, invasion, hemostasis
and inflammation in either physiological or pathological
processes [159,167,169,170].
In physiology, MMPs are involved in diverse biological
mechanisms ranging from wound repair to pregnancy
[155,157,159,167]. In pathology, MMP dysfunction has
been implicated in cancer, cardio-vascular diseases, em-
physema, acute renal failure, ophthalmic pathologies, neu-
roinflammation, neurodegenerative disorders, autoimmune
diseases [156-160,167,169,170] and, very recently, malaria
[2,151-154].
Matrix metalloproteinases and animal models
In vivo mouse models of CM have recently implicated
MMP dysfunction in disease pathology, although it should
be kept in mind that experimental CM presents important
differences compared to human CM, such as leukocyte
sequestration in cerebral microvessels and subsequent mi-
gration into brain parenchyma [49]. An excellent study
performed by Van den Steen and his group comprehen-
sively investigated mRNA expression levels of MMPs and
protein release or pro-enzyme activation in five differ-
ent organs (brain, lung, spleen, liver, and kidney) from
CM-sensitive C57B1/6 mice infected with P. berghei ANKA
(CM model) or P. berghei NK65 (non-CM model) and
CM-resistant Balb/C mice infected with P. berghei ANKA
(CM-resistant model) [172]. Importantly, they observed en-
hanced expression and activation of monocytic (CD11b+)
MMP-9 in brains of CM mice [172] specific to CM, as sug-
gested by comparison with non-CM models, such as lung
pathology [173]. Additionally, tissue-specific increases in
mRNA expression were found for several MMPs, in-
cluding MMP-3, -4, -8, and -13 in spleen, MMP-8, -12, -13,
and -14 in liver, and MMP-8 and -13 in brain. All of these
increases were more pronounced in the CM model. In a
CM-resistant model, MMP-3 expression was significantlyenhanced, suggesting a protective role for this MMP in CM
[172]. In another study, CM mice showed increased neural
MMP-7 protein levels [151]. Interestingly, urokinase-type
plasminogen activator (uPA) -/- or urokinase-type plas-
minogen activator receptor (uPAR) -/- knock-out mice
with CM displayed enhanced survival and attenuated
thrombocytopenia [174].
A parasite molecule, malarial pigment Hz - a lipid-
bound ferriprotoporphyrin IX produced by P. falciparum
after hemoglobin catabolism [175] - is proposed to play
a role in experimental CM. Indeed, using a sensitive
fluorometric method to determine Hz content in blood
and tissue samples from mice infected with P. berghei
NK65 (non-CM model) or ANKA (CM model), Sullivan
and colleagues observed increased Hz levels in tissue
correlating with the duration of infection, with neural
Hz levels being higher in CM than non-CM mice, rais-
ing the possibility that Hz presence may be associated
with cerebral pathology [176].
Interestingly, in vitro, Hz appears to play a major role
in MMP dysfunction. Phagocytosis of Hz by RAW 264.7
rat macrophage cell line was shown to impair expression
of several inflammatory molecules [177] and, after an
early inhibitory peak, to increase the long-term mRNA
expression of MMP-9 [178]. This effect was related to the
lipid moiety of Hz, since lipid-free synthetic Hz (β-hematin)
did not modulate MMP-9 expression. The Hz-dependent
enhancement of MMP-9 transcription and protein re-
lease was mimicked by 4-hydroxy-2-nonenal (4-HNE)
[178], a molecule generated by Hz from polyunsaturated
fatty acids [179].
Matrix metalloproteinases and human studies
In vitro studies using human monocytes and endothelial
cells [152,180-195] provide convincing and homoge-
neous evidence for Hz-dependent mechanisms underlying
aberrant MMP-9 function (see Figure 4). In a series of
works performed with human adherent or immunopurified
monocytes from peripheral blood, the phagocytosis of free
Hz or Hz-containing trophozoites enhanced MMP-9
mRNA levels, protein expression, and activity [180-186].
This observation was also investigated using THP-1 mono-
cyte cell line [187]. Hz-fed monocytes display increased
total gelatinolytic activity [186] and invasiveness [180]
caused by MMP-9 - but not MMP-2 [188] - enhancement.
Increased MMP-9 function in human monocytes ap-
pears to be mediated by Hz-dependent over-production
of several pro-inflammatory molecules, including TNF-α
[180], IL-1β [181], and CCL-3/MIP-1α [184]. Further in-
vestigation revealed increases in MMP-9 [181], TNF-α
[189,190] and IL-1β [181,190], but not CCL-3/MIP-1α
[183,190], were dependent on the lipid moiety of Hz.
These studies unveiled a major role for 15-HETE, a potent
lipid peroxidation derivative generated by Hz autocatalysis.
Figure 4 Principal mechanisms underlying Hz-dependent dysregulation of matrix metalloproteinase-9 (MMP-9) and related molecules
in human monocytes. The most relevant Hz-dependent mechanisms underlying aberrant MMP-9 function in malaria are based on current
evidence from in vitro models of cultured human monocytes. After Hz phagocytosis, some lipoperoxidation products generated by Hz autocatalysis
such as 15-HETE can promote early and late activation of PKC and p38 MAPK. These kinases have been associated with cytosolic I-kBα phosphorylation
and degradation, resulting in subsequent nuclear translocation of NF-kB p50 and p65 subunits. Consequently, the transcription and protein expression
of several pro-inflammatory molecules including TNF-α, IL-1β, and MIP-1α, and of some proteolytic enzymes or inhibitors such as lysozyme, pro-MMP-9,
and TIMP-1 is enhanced. p38 MAPK can also promote monocyte degranulation, releasing pro-MMP-9, TIMP-1 and lysozyme into the extracellular
environment. After secretion of these molecules, several proteolytic events can occur. Active MMP-9, generated from MMP-3 processing of the
pro-enzyme, can further modulate TNF-α shedding from cell membrane in a similar manner as TACE, whereas ICE activates IL-1β after cleaving its
pro-peptide. Soluble TNF-α, IL-1β, and MIP-1α have been shown to play a key role in mediating Hz effects on MMP-9, lysozyme, and TIMP-1
production, possibly generating some auto-enhancing loops. Hz-enhanced MMP-9 could favour CM development through complementary
proteolytic activities (see Figure 5). On the other hand, TIMP-1 is primarily referred to as a MMP-9 inhibitor, thus TIMP-1 Hz-enhanced levels could
supposedly be protective. However, several MMP-independent functions such as inhibition of cell apoptosis and growth have been recently described
for TIMP-1. Thus, Hz-enhanced TIMP-1 protein may play a role in prolonged survival of impaired Hz-fed monocytes, in their altered maturation to
dendritic cells and in their reduced ability to coordinate erythropoiesis. Finally, enhanced plasma levels of human lysozyme have been depicted as a
risk factor for severe malaria.
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zyme release from human adherent monocytes, two
molecules stored in gelatinase granules along with
MMP-9 [186,190-192]. Further studies also showed that
Hz-induced monocyte degranulation was mediated by TNF-
α, IL-1β and MIP-1α/CCL-3 [191,192] and dependent on
Hz lipid moiety, suggesting a major role for 15-HETE [190].
The heme core of Hz was shown to bind MMP-9 hemo-
pexin domain and to prime the activation of the zymogenby other MMPs, such as MMP-3 [193]. The mechanisms
underlying Hz-dependent enhancement of MMP-9, TNF-
α, IL-1β, CCL-3/MIP-1α, TIMP-1 and lysozyme appear to
involve NF-kB activation, as suggested by results from
parallel works performed with adherent monocytes from
peripheral blood [182,186,190,191] and THP-1 cell line
[187]. In these works, Hz-induced enhancement of MMP-
9, TNF-α, IL-1β, CCL-3/MIP-1α and TIMP-1, as well as
total gelatinolytic and lysozyme activity were abrogated by
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properties (quercetin, artemisinin, parthenolide, and ex-
tracts from Punica granatum). Moreover, results from ex-
periments with SB203580, a known inhibitor of p38
MAPK pathway suggest that concurrent activation of p38
MAPK pathway seems to be mandatory for Hz- and
15-HETE-dependent increased MMP-9 [185] and related
molecules TNF-α, IL-1β, CCL-3/MIP-1α, TIMP-1 and
lysozyme [186,190,191]. On the contrary, ERK and JNK
MAPK pathways do not seem to be activated by Hz [185].
Additional evidence on Hz-dependent MMP dysregu-
lation is also derived from studies using human endothe-
lial cells. In the human microvascular endothelial cell
line HMEC-1, either free Hz [194] or Hz-containing-
iRBCs [195] induced the release of pro-MMP-9 and active
MMP-9 proteins de novo without altering pro-MMP-2
basal levels. Interestingly, Hz also enhanced the protein
levels of basal MMP-1 and MMP-3, two MMPs sequen-
tially involved in pro-MMP-9 activation. Consequently,
total gelatinolytic activity and cell invasion were increased.
More evidence of Hz-triggered enhancement of MMP-9
protein release emerges from studies using human endo-
thelial cells from large calibre vessels [152]. Similar to
human monocytes, a role for the Hz lipid moiety also
appears likely in endothelial cells, although the mole-
cules responsible for these effects have not yet been
identified [194].
Little evidence exists on the in vivo involvement of
MMPs in human CM from organ autopsy studies or from
fluid (blood, serum) analysis of patients with uncompli-
cated or severe malaria [65,196-201]. The little data that
does exist are somehow conflicting and still incomplete.
The accumulation of pro-angiogenic uPAR [196], MMP-
1 and VEGF [197] in Durck granulomas, along with the
lack of anti-angiogenic endostatin/collagen XVIII in ring
haemorrhage areas [198] has been observed in the brains of
patients with fatal CM, suggesting that the proMMP-9 pro-
teolytic machinery is activated in areas of intense parasite
sequestration and vascular damage. Consistently, micro-
array analysis performed on whole blood from Kenyan chil-
dren with severe malaria showed P. falciparum activation
of the human MMP-9 gene [199].
However, sera of Gabonese and Ghanaian children with
uncomplicated or severe malaria did not display altered
MMP-9 levels [65,200]. Moreover, serum MMP-8 levels
were elevated in Gabonese children with either uncompli-
cated malaria or CM [200], but not in Nigerian children
with uncomplicated malaria [201]. Nonetheless, it has
been argued that serum levels might not be an ideal
source for reliable data concerning MMP levels, since
MMP release from blood cells during sample processing
might give a highly non-specific background result, thus
hindering the ability to assess true concentrations of circu-
lating MMPs [202].Possible role of matrix metalloproteinases in
pathophysiology and therapy of cerebral malaria
It is likely that MMPs play an active role in several
steps during CM development as they can process a
large repertoire of substrates [169-171], including pro-
inflammatory molecules, tight junctions, and hemostatic
factors likely involved in CM (see Figure 5 and Tables 4
and 5).
First, MMPs proteolytically cleave the pro-forms of
many cytokines and chemokines reportedly enhanced in
CM, including TNF-α, IL-1β, CXCL-8/IL-8. As a result
of cleavage, these molecules are shed, activated or func-
tionally potentiated, respectively. Thus, MMPs could
contribute to the uncontrolled inflammatory response
typical of CM. Consistently, an in vitro study using ad-
herent monocytes demonstrated a Hz-dependent patho-
logical auto-enhancing loop established between MMP-9
and TNF-α [180].
Moreover, a growing number of inter-endothelial
tight junctions, including occludin, ZO-1, claudin-1
and claudin-5 are known MMP substrates (e.g. MMP-2,
MMP-3, MMP-7 and MMP-9), which raises the possibility
that MMP activity on these substrates can enhance the
permeability of endothelial barriers by destroying these
junctions [203-209]. Therefore, enhanced MMP levels in
malaria might facilitate BBB leakage. This hypothesis is
consistent with data showing that Hz-containing iRBCs
reduced human BBB permeability in vitro [102], and that
Hz and iRBCs enhanced MMP-1, MMP-3 and MMP-9
produced by human microvascular endothelium [194,195].
Finally, MMPs can also influence hemostasis. Both tPA
and uPA molecules, responsible for plasminogen conver-
sion to plasmin, as well as tPA/uPA inhibitor PAI-1 can be
processed by MMPs [210-212]. As a consequence, MMPs
might affect fibrin degradation by plasmin, perhaps explain-
ing thrombotic events that frequently occur during CM.
Interestingly, some molecules such as 4-aminoquinolines
and artemisinins, which are currently used for primary
therapy of uncomplicated malaria, have displayed MMP-
inhibiting properties. Chloroquine treatment reduces
MMP-9 serum levels in patients with systemic lupus
erythematosus [213]. Artemisinin down-regulates MMP-2
levels in human melanoma cells [214] and MMP-1, MMP-2
and MMP-9 levels in mouse embryonic stem-cells derived
from embryoid bodies [215]. Dihydroartemisinin inhibits
MMP-2, MMP-9 and MMP-14 expression/activity in hu-
man fibrosarcoma cells [216] and MMP-9 expression in
human umbilical vein endothelial cells [217]. Finally, arte-
sunate down-regulates MMP-2 and MMP-7 expression in
human non-small cell lung cancer [218]. However, it
should be noticed that the drug concentrations used in
such studies need to be verified and optimized for human
clinical trials. This might explain why antimalarial drugs
alone cannot prevent CM development.
Figure 5 Multiple putative roles of matrix metalloproteinases (MMPs) in cerebral malaria (CM) according to their biochemical
functions. MMPs could play an active role during CM development through several complementary mechanisms: i) by disrupting endothelial
tight junctions after protein degradation of ZO-1, claudins and occludin, thus causing an increased BBB permeability; ii) by promoting TNF-α
shedding, IL-1β activation and CXCL8/IL-8 potentiation after proteolytic cleavage of their pro-domains, therefore inducing exacerbated
pro-inflammatory response; iii) by processing some CM-associated hemostatic factors such as tpA, upA, and PAI-1, thus increasing the risk
for thrombotic events.
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with broad spectrum or specific MMP inhibitors as adju-
vant therapy in CM. In the last two decades, a large num-
ber of synthetic MMP inhibitors have gone through
clinical trials and largely failed as anti-cancer and
anti-arthritis drugs due to serious long-term side ef-
fects, with only one currently commercially available
[219-223]. Hopefully, using combinations of MMP in-
hibitors with antimalarials could justify lower therapeutic
doses of both drugs, thereby reducing their potential side
effects whilst still enhancing anti-MMP properties by drug
synergy. To date, the effects of MMP inhibitors in CM
remain scarce. In vitro, the use of a specific synthetic in-
hibitor of MMP-9 was shown to abrogate Hz-dependentTable 4 Cerebral malaria (CM)-associated brain inter-endothe
hypothesized to be matrix metalloproteinase (MMP) substrat
MMP MMP substrate: junctions
MMP-1 Collagen I/II/III/VII/VIII/X; Aggrecan; Entactin; Tenascin
MMP-3 Collagen II/IV/IX/X; Claudin-5; E-cadherin; Elastin; Fibrone
Laminin; Occludin; Selectin; ZO-1
MMP-8 Collagen I/II/III/V/VII/VIII/X; Claudin-5; Laminin; Occludin;
MMP-9 Collagen IV/V/VII/X/XIV; Aggrecan; Claudin-5; E-cadherin
lastin; Fibronectin; Laminin; Occludin; Vitronectin; ZO-
MMP-12 Elastin; Fibronectin; Laminin; Proteoglycans
MMP-13 Collagen I/II/III/IV/V/IX; Aggrecan; Elastin; Fibronectin; Laminin
MMP-14 Collagen I/II/III; E-cadherin; αvβ4 integrin; Aggrecan;
Fibronectin; Laminin; Vitronectinincrease of TNF-α in human monocytes, suggesting that
MMP-9 inhibition might be useful to counteract patho-
logical inflammation in CM [180]. However, MMP-9
knock-out mice infected with P. berghei ANKA did not
display any protection from CM development, probably
due to the redundant functions of other MMPs which
might compensate for the loss of MMP-9 [172]. On the
contrary, treatment with broad-spectrum MMP inhibitor
BB-94 significantly improved survival of CM mice [172].
Future research aimed at determining the exact role
(protective or detrimental) of each MMP during malaria
infections will be highly informative. Unfortunately, with
the exception of a few cases, specific inhibitors against
individual MMPs are currently lacking [224-226]. Somelial junctions and cell-matrix adhesion molecules known/
es
Junction type
Cell-matrix adhesion
ctin; Cell-matrix adhesion; Adherens junctions; Tight junctions
ZO-1 Cell-matrix adhesion; Tight junctions
; E
1
Cell-matrix adhesion; Adherens junctions; Tight junctions
Cell-matrix adhesion
; Tenascin Cell-matrix adhesion
Cell-matrix adhesion; Adherens junctions
Table 5 Cerebral malaria (CM)-associated
pro-inflammatory molecules known/hypothesized to be
matrix metalloproteinase (MMP) substrates
MMP MMP substrate: cytokine MMP substrate: chemokine
MMP-1 IL-1β CCL-2/MCP-1/JE
TNF-α CCL-25/TECK
MMP-2 IL-1β CCL-2/MCP-1/JE
TGF-β CCL-11/Eotaxin
TNF-α CCL-25/TECK
CXCL-1/GRO-α/KC
CXCL-2/GRO-β/MIP-2
CXCL-12/SDF-1
MMP-3 proIL-1β CCL-2/MCP-1/JE
proTNF-α
MMP-7 proTNF-α
MMP-8 CCL-2/MCP-1/JE
CXCL-5/ENA-78/LIX
MMP-9 IL-1β CXCL-1/GRO-α/KC
IL2-R CXCL-2/GRO-β/MIP-2
TGF-β CXCL-4/PF-4
proTNF-α CXCL-5/ENA-78/LIX
CXCL-10/IP-10
CXCL-12/SDF-1
CCL-5/RANTES
CCL-7/MCP-3/MARC
CCL-17/TARC
CCL-25/TECK
MMP-10 CCL-25/TECK
MMP-11 CCL-25/TECK
MMP-12 CXCL-3/GRO-γ
CXCL-9/MIG
CXCL-10/IP-10
CXCL-11/I-TAC
MMP-14 proTNF-α CXCL-8/IL-8
CXCL-12/SDF-1
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for example to perform hemoglobin degradation [227].
Therefore, MMP inhibitors may not only influence host
but also parasitic pathways. Another issue to be taken in
account is represented by the effects of MMPs on other
organs than brain. However, it should be noted that the
adverse effects of MMP inhibitors documented in other
pathologies such as cancer were associated with long-term
treatment [220], whereas the time course of drug adminis-
tration in CM therapy should be reasonably shorter, pos-
sibly limiting the development of side effects. A detailed
analysis of the role of each protease in physiology andpathology, along with the development of specific inhibi-
tors, could yield novel insights to assess whether specific
MMP inhibition might be considered as new adjuvant
therapies.
Conclusion
As suggested by three complementary theories devel-
oped over the past century, CM might be a likely conse-
quence of several concomitant phenomena, including
iRBC sequestration in brain microvessels, enhanced BBB
permeability, and release of pro-inflammatory molecules
from host immune cells. Data from in vitro and in vivo
studies suggest that a full BBB breakdown during CM is
more likely to occur in mouse than in humans. In the
latter case, the BBB appears only mildly impaired as a
result of tight junction disruption. MMPs are host proteo-
lytic enzymes involved in degradation of basement mem-
branes, disruption of inter-endothelial tight junctions,
and cleavage of a large spectrum of pro-inflammatory,
membrane-bound and hemostasis-related molecules, and
they may play a crucial role in CM. Further in-depth ana-
lysis of the involvement of MMPs in CM might help to
design new adjuvant therapies. In this context, MMP in-
hibitors could prevent BBB leakage and reduce the exacer-
bated inflammatory response, thus reducing the high
mortality rates of CM patients, along with the frequency
of neurological sequelae in recovering patients.
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